3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Sell
36
APNHY Quote, Financials, Valuation and Earnings
Last price:
$9.26
Seasonality move
:
1.79%
Day range:
$9.25 - $9.26
52-week range:
$8.26 - $13.69
Dividend yield:
2.24%
P/E ratio:
15.56x
P/S ratio:
1.72x
P/B ratio:
0.91x
Volume:
2.5K
Avg. volume:
439
1-year change:
-15.63%
Market cap:
$4.1B
Revenue:
$2.4B
EPS (TTM):
$0.53
Analysts' Opinion
-
Consensus RatingAspen Pharmacare Holdings has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Aspen Pharmacare Holdings has an estimated downside of -- from its current price of $9.26.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $9.26.
Fair Value
-
According to the consensus of 0 analysts, Aspen Pharmacare Holdings has -- downside to fair value with a price target of -- per share.
APNHY vs. S&P 500
-
Over the past 5 trading days, Aspen Pharmacare Holdings has underperformed the S&P 500 by -2.86% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Aspen Pharmacare Holdings does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aspen Pharmacare Holdings has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Aspen Pharmacare Holdings reported revenues of --.
Earnings Growth
-
Aspen Pharmacare Holdings earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Aspen Pharmacare Holdings reported earnings per share of --.
Enterprise value:
5.4B
EV / Invested capital:
--
Price / LTM sales:
1.72x
EV / EBIT:
12.60x
EV / Revenue:
2.24x
PEG ratio (5yr expected):
--
EV / Free cash flow:
143.72x
Price / Operating cash flow:
110.23x
Enterprise value / EBITDA:
12.60x
Gross Profit (TTM):
$1B
Return On Assets:
3.21%
Net Income Margin (TTM):
9.85%
Return On Equity:
5.16%
Return On Invested Capital:
3.7%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2011-12-31 | 2012-12-31 | 2013-12-31 | 2012-12-31 | 2013-12-31 | |
| Income Statement | ||||||
| Revenue | $1.9B | $2B | $2.3B | $1.1B | $1.1B | |
| Gross Profit | $891.3M | $957.7M | $1.1B | $515.2M | $530.3M | |
| Operating Income | $479.7M | $524.6M | $553.8M | $293.2M | $273.8M | |
| EBITDA | $502.7M | $559M | $578.7M | $293.2M | $273.8M | |
| Diluted EPS | $0.87 | $0.78 | $0.84 | $0.43 | $0.40 | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.1B | $2.3B | $2.1B | $2.4B | $2.3B | |
| Total Assets | $7.7B | $7.6B | $6.9B | $7.2B | $7.4B | |
| Current Liabilities | $1B | $2.6B | $1.4B | $1.2B | $1.3B | |
| Total Liabilities | $3.7B | $3.1B | $2.5B | $2.6B | $2.9B | |
| Total Equity | $4B | $4.6B | $4.4B | $4.6B | $4.5B | |
| Total Debt | $2.4B | $1.7B | $1.4B | $1.6B | $1.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2011-12-31 | 2012-12-31 | 2013-12-31 | 2012-12-31 | 2013-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $407.8M | $360.4M | $398M | $155.2M | $111.8M | |
| Cash From Investing | -$944.4M | -$694.4M | -$1.8B | -$443.9M | -$1.4B | |
| Cash From Financing | $379.1M | $353.6M | $2B | $312.4M | $1.9B | |
| Free Cash Flow | $265.1M | -$318M | $233.8M | -$288.3M | $10.6M | |
APNHY
Sector
Market Cap
$4.1B
$48.9M
Price % of 52-Week High
67.63%
49.34%
Dividend Yield
2.24%
0%
Shareholder Yield
-0.49%
-0.74%
1-Year Price Total Return
-15.63%
-30.56%
Beta (5-Year)
1.121
0.754
Dividend yield:
2.24%
Annualized payout:
$0.18
Payout ratio:
34.49%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$8.94
200-day SMA
Sell
Level
$11.40
Bollinger Bands (100)
Sell
Level
9.3 - 11.72
Chaikin Money Flow
Sell
Level
-1.3M
20-day SMA
Buy
Level
$9.23
Relative Strength Index (RSI14)
Buy
Level
50.19
ADX Line
Sell
Level
45.27
Williams %R
Neutral
Level
-26.2963
50-day SMA
Sell
Level
$9.54
MACD (12, 26)
Sell
Level
-0.23
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Sell
Level
-2.3M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.4614)
Buy
CA Score
(Annual)
Level (0.5034)
Buy
Beneish M-Score
(Annual)
Level (-2.5172)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-1.1756)
Buy
Piotroski F Score
(Annual)
Level (5)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aspen Pharmacare Holdings Ltd is a specialty pharmaceutical company with a commercial footprint covering more than 50 countries and complex manufacturing capabilities in both API and finished dose form. The company focuses on a broad range of post-patent, branded medicines and domestic brands spanning many therapeutic areas. The company has four business segments such as Active Pharmaceutical Ingredients (API) – this segment includes the API Chemicals business and non-heparin biochemical API business, Heparin – this segment includes the full value chain contribution from all heparin containing products including API and Finished Dose. Form (FDF) sales Key products include the Fraxiparine and MonoEmbolex heparin containing FDF products and FDF Steriles segment.
Stock Forecast FAQ
In the current month, APNHY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The APNHY average analyst price target in the past 3 months is --.
-
Where Will Aspen Pharmacare Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aspen Pharmacare Holdings share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Aspen Pharmacare Holdings?
Analysts are divided on their view about Aspen Pharmacare Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aspen Pharmacare Holdings is a Sell and believe this share price will rise from its current level to --.
-
What Is Aspen Pharmacare Holdings's Price Target?
The price target for Aspen Pharmacare Holdings over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is APNHY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aspen Pharmacare Holdings is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of APNHY?
You can purchase shares of Aspen Pharmacare Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aspen Pharmacare Holdings shares.
-
What Is The Aspen Pharmacare Holdings Share Price Today?
Aspen Pharmacare Holdings was last trading at $9.26 per share. This represents the most recent stock quote for Aspen Pharmacare Holdings. Yesterday, Aspen Pharmacare Holdings closed at $9.26 per share.
-
How To Buy Aspen Pharmacare Holdings Stock Online?
In order to purchase Aspen Pharmacare Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will American Tower Stock Recover?
The performance of the real estate investment trust, or REIT,…
Will Booking Holdings Stock Split?
Booking Holdings, the travel and technology company that owns brands…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 22.08% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is down 8.01% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is down 0.86% over the past day.
